EPA/690/R-19/003F | September 2019 | FINAL Provisional Peer-Reviewed Toxicity Values for 2-Nitropropane (CASRN 79-46-9) U.S. EPA Office of Research and Development Center for Public Health and Environmental Assessment EPA/690/R-19/003F FINAL September 2019 Provisional Peer-Reviewed Toxicity Values for 2-Nitropropane (CASRN 79-46-9) Center for Public Health and Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency Cincinnati, OH 45268 ii 2-Nitropropane AUTHORS, CONTRIBUTORS, AND REVIEWERS CHEMICAL MANAGERS Jon Reid, PhD, DABT Center for Public Health and Environmental Assessment, Cincinnati, OH J. Phillip Kaiser, PhD, DABT Center for Public Health and Environmental Assessment, Cincinnati, OH CONTRIBUTOR Scott C. Wesselkamper, PhD Center for Public Health and Environmental Assessment, Cincinnati, OH DRAFT DOCUMENT PREPARED BY SRC, Inc. 7502 Round Pond Road North Syracuse, NY 13212 PRIMARY INTERNAL REVIEWERS J. Allen Davis, MSPH Center for Public Health and Environmental Assessment, Cincinnati, OH Dan D. Petersen, PhD, DABT Center for Public Health and Environmental Assessment, Cincinnati, OH This document was externally peer reviewed under contract to: Eastern Research Group, Inc. 110 Hartwell Avenue Lexington, MA 02421-3136 Questions regarding the contents of this document may be directed to the U.S. EPA Office of Research and Development’s Center for Public Health and Environmental Assessment. To the memory of Dr. Jon Brice Reid (1937−2019) iii 2-Nitropropane TABLE OF CONTENTS COMMONLY USED ABBREVIATIONS AND ACRONYMS...................................................... v BACKGROUND .................................................................................................................................. 1 DISCLAIMERS .................................................................................................................................... 1 QUESTIONS REGARDING PPRTVs ............................................................................................... 1 INTRODUCTION ................................................................................................................................ 2 REVIEW OF POTENTIALLY RELEVANT DATA (NONCANCER AND CANCER) .............. 6 HUMAN STUDIES ....................................................................................................................... 14 ANIMAL STUDIES ...................................................................................................................... 16 Oral Exposures............................................................................................................................ 16 Inhalation Exposures .................................................................................................................. 19 OTHER DATA (SHORT-TERM TESTS, OTHER EXAMINATIONS) .................................. 29 Genotoxicity Studies .................................................................................................................. 29 Supporting Human Toxicity Studies ......................................................................................... 48 Supporting Animal Toxicity Studies ......................................................................................... 49 Absorption, Distribution, Metabolism, and Elimination Studies ............................................ 60 Mode-of-Action/Mechanistic Studies ....................................................................................... 61 DERIVATION OF PROVISIONAL VALUES ............................................................................... 63 DERIVATION OF ORAL REFERENCE DOSES ...................................................................... 63 DERIVATION OF INHALATION REFERENCE CONCENTRATIONS ............................... 64 Derivation of Subchronic Provisional Reference Concentration ............................................ 64 Derivation of Chronic Provisional Reference Concentration .................................................. 68 CANCER WEIGHT-OF-EVIDENCE DESCRIPTOR................................................................ 68 MODE-OF-ACTION DISCUSSION ............................................................................................ 69 DERIVATION OF PROVISIONAL CANCER POTENCY VALUES ..................................... 71 Derivation of Provisional Oral Slope Factor ............................................................................ 71 Derivation of Provisional Inhalation Unit Risk ........................................................................ 71 APPENDIX A. SCREENING PROVISIONAL VALUES ............................................................. 72 APPENDIX B. DATA TABLES ....................................................................................................... 78 APPENDIX C. BENCHMARK DOSE MODELING RESULTS ................................................ 117 APPENDIX D. REFERENCES ....................................................................................................... 139 iv 2-Nitropropane COMMONLY USED ABBREVIATIONS AND ACRONYMS1 α2u-g alpha 2u-globulin MN micronuclei ACGIH American Conference of Governmental MNPCE micronucleated polychromatic Industrial Hygienists erythrocyte AIC Akaike’s information criterion MOA mode of action ALD approximate lethal dosage MTD maximum tolerated dose ALT alanine aminotransferase NAG N-acetyl-β-D-glucosaminidase AR androgen receptor NCI National Cancer Institute AST aspartate aminotransferase NOAEL no-observed-adverse-effect level atm atmosphere NTP National Toxicology Program ATSDR Agency for Toxic Substances and NZW New Zealand White (rabbit breed) Disease Registry OCT ornithine carbamoyl transferase BMD benchmark dose ORD Office of Research and Development BMDL benchmark dose lower confidence limit PBPK physiologically based pharmacokinetic BMDS Benchmark Dose Software PCNA proliferating cell nuclear antigen BMR benchmark response PND postnatal day BUN blood urea nitrogen POD point of departure BW body weight PODADJ duration-adjusted POD CA chromosomal aberration QSAR quantitative structure-activity CAS Chemical Abstracts Service relationship CASRN Chemical Abstracts Service registry RBC red blood cell number RDS replicative DNA synthesis CBI covalent binding index RfC inhalation reference concentration CHO Chinese hamster ovary (cell line cells) RfD oral reference dose CL confidence limit RGDR regional gas dose ratio CNS central nervous system RNA ribonucleic acid CPHEA Center for Public Health and SAR structure activity relationship Environmental Assessment SCE sister chromatid exchange CPN chronic progressive nephropathy SD standard deviation CYP450 cytochrome P450 SDH sorbitol dehydrogenase DAF dosimetric adjustment factor SE standard error DEN diethylnitrosamine SGOT serum glutamic oxaloacetic DMSO dimethylsulfoxide transaminase, also known as AST DNA deoxyribonucleic acid SGPT serum glutamic pyruvic transaminase, EPA Environmental Protection Agency also known as ALT ER estrogen receptor SSD systemic scleroderma FDA Food and Drug Administration TCA trichloroacetic acid FEV1 forced expiratory volume of 1 second TCE trichloroethylene GD gestation day TWA time-weighted average GDH glutamate dehydrogenase UF uncertainty factor GGT γ-glutamyl transferase UF A interspecies uncertainty factor GSH glutathione UFC composite uncertainty factor GST glutathione-S-transferase UFD database uncertainty factor Hb/g-A animal blood-gas partition coefficient UFH intraspecies uncertainty factor Hb/g-H human blood-gas partition coefficient UFL LOAEL-to-NOAEL uncertainty factor HEC human equivalent concentration UFS subchronic-to-chronic uncertainty factor HED human equivalent dose U.S. United States of America i.p. intraperitoneal WBC white blood cell IRIS Integrated Risk Information System IVF in vitro fertilization LC50 median lethal concentration LD50 median lethal dose LOAEL lowest-observed-adverse-effect level 1Abbreviations and acronyms not listed on this page are defined upon first use in the PPRTV document. v 2-Nitropropane FINAL September 2019 PROVISIONAL PEER-REVIEWED TOXICITY VALUES FOR 2-NITROPROPANE (CASRN 79-46-9) BACKGROUND A Provisional Peer-Reviewed Toxicity Value (PPRTV) is defined as a toxicity value derived for use in the Superfund Program. PPRTVs are derived after a review of the relevant scientific literature using established Agency guidance on human health toxicity value derivations. All PPRTV assessments receive internal review by at least two Center for Public Health and Environmental Assessment (CPHEA) scientists and an independent external peer review by at least three scientific experts. The purpose of this document is to provide support for the hazard and dose-response assessment pertaining to chronic and subchronic exposures to substances of concern, to present the major conclusions reached in the hazard identification and derivation of the PPRTVs, and to characterize the overall confidence in these conclusions and toxicity values. It is not intended to be a comprehensive treatise on the chemical or toxicological nature of this substance. Currently available PPRTV assessments can be accessed on the U.S. EPA’s PPRTV website at https://www.epa.gov/pprtv. PPRTV assessments are eligible to be updated on a 5-year cycle to incorporate new data or methodologies that might impact the toxicity values or characterization of potential for adverse human-health effects and are revised as appropriate. Questions regarding nomination of chemicals